Clay Siegall is the President, Chief Executive Officer, Chairman of Board and the Co-founder of Seattle Genetics, which was established in 1998. He attained his Ph.D. in Genetics from the University of George Washington and a Bsc Zoology from the University of Maryland. Being a trained Scientist, he is an expert who handles cancer therapies.
On a foundation of Scientific Innovation, drug development practices, rigorous research, and his known passion of helping out the cancer patients, he built Seattle Genetics. His management prowess in the company has led it to the current leadership positions. This has enabled it to develop the Anti-Drug Conjugates (ADC’s) and also secure FDA approval of its products. One of its first products known as the ADCETRIS is a new global brand that is currently approved in more than 65 countries.
Dr. Siegall’s leadership has led to Seattle Genetics earning multiple strategy licenses for its ADC technology that includes Genentech (Roche), SmithKline, Abbvie, and Pfizer that have earned it over $350 million to date. There are more than 20 ADC’s using Seattle Genetics technology across internal and collaborate programs.
In his blog’s recent posts, he gives a breakthrough for cancer treatment. He announced the creation of a new class of drugs known as Antibody- Drug Conjugate that is set to improve cancer treatment. This combination of antibodies will help the body receive the drugs without causing any health problem associated with chemotherapy to the patient.
Dr. Clay Siegall also indicates that the success of these drugs has attracted the attention of known pharmaceutical companies all over the world. Seattle Genetic organization is using this advertised drug, ADCETRIS, in most cancer treatment institutions. According to Siegall, the drug is under examination in more than 70 researches on several types of lymphomas.
Dr. Siegall also co-founded Squibb Pharmaceuticals Research Institute with Bristol-Myers from 1991 to1997, National Cancer Institute and National Institute of Health from 1991 to 1998. He serves on Boards of Directors of Ultragenyx Pharmaceutical, Alder BioPharmaceuticals, and Washington Roundtable. He is also an Author of more than 70 publications.
Dr.Siegall has spent most of his years researching on cancer treatment. Seattle Genetics Firm made his name prominent. He is currently working with large pharmaceutical companies to sell the products they have designed. He also plans on adding more personnel to the community. He has received several awards. In 2013, he got an Award from Maryland University as Alumnus of the year for computer, math and sciences. In 2012, he received an award from Pacific Northwest Ernst as the Young Entrepreneur of the year.